Advent Pharma Ltd.
DDSE:ADVENT13.10
BDT
-0.10
(-0.76%)
ISIN
BD0492ADVPL9
Return %
Stock
S&P 500
1Y
-10.88
14.20
3Y
-43.04
81.12
5Y
-53.60
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Faria Binta Alam
- Full Time Employees
- 317
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Ramna Bangladesh
- IPO Date
- Apr 12, 2018
- Website
- adventpharmabd.com
- Similar Companies
- Business
- Advent Pharma Limited is a Bangladesh-based pharmaceutical company that specializes in the manufacturing, importing, marketing, and distribution of animal healthcare medicines, nutritional supplements, and feed additives for livestock, poultry, and aquaculture. The company operates across multiple veterinary therapeutic segments and delivers products in various dosage forms, including bolus formulations, such as antibacterial, anthelmintic, anti-inflammatory, and antihistaminic tablets; water-soluble and oral powders, comprising antibiotic formulations, digestive stimulants, antiprotozoals, and anticoccidials; liquid oral solutions and suspensions, including broad-spectrum antimicrobials, respiratory expectorants, and electrolytes; and veterinary injectable solutions and nutritional additives, covering multivitamins, multiminerals, calcium supplements, growth promoters, and enzyme complexes marketed under proprietary brand names such as Ad-Tetra, Adensin, Adcipcin, Adrizol, Adminide, Adfen, Benadex, AD-HISTA Vet, ADBOVI, ADCAL-P, and Adprolim-Plus. Founded in 2007 and headquartered in Ramna, Dhaka, Bangladesh, the company operates a dedicated production facility at the BSCIC Industrial Estate in Dhamrai, Dhaka, serving veterinary practitioners, commercial farms, and agricultural distributors across Bangladesh. In recent developments, Advent Pharma Limited has focused on upgrading production efficiency across its bolus and liquid manufacturing lines to meet domestic Good Manufacturing Practice standards, adapting its capital management and shareholder return processes following regulatory classification adjustments on the Dhaka Stock Exchange and Chittagong Stock Exchange, and broadening its livestock wellness offerings with enhanced mineral-vitamin formulations and targeted antibiotic lines to address growing local market demand.